Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Selective cyclooxygenase-2 inhibitors.

B D Golden1, S B Abramson

  • 1Department of Rheumatology, Hospital for Joint Diseases, New York, New York, USA.

Rheumatic Diseases Clinics of North America
|June 5, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety, tolerability, and pharmacodynamics of an anti-interleukin-1α/β dual variable domain immunoglobulin in patients with osteoarthritis of the knee: a randomized phase 1 study.

Osteoarthritis and cartilage·2017
Same author

Plasma levels of interleukin-1 receptor antagonist (IL1Ra) predict radiographic progression of symptomatic knee osteoarthritis.

Osteoarthritis and cartilage·2015
Same author

Inflammation (or synovitis)-driven osteoarthritis: an opportunity for personalizing prognosis and treatment?

Scandinavian journal of rheumatology·2015
Same author

TSG-6 activity as a novel biomarker of progression in knee osteoarthritis.

Osteoarthritis and cartilage·2013
Same author

Enhanced COMP catabolism detected in serum of patients with arthritis and animal disease models through a novel capture ELISA.

Osteoarthritis and cartilage·2012
Same author

Glatiramer acetate (GA), the immunomodulatory drug, inhibits inflammatory mediators and collagen degradation in osteoarthritis (OA) cartilage.

Osteoarthritis and cartilage·2011

Cyclooxygenase-2 (COX-2) selective inhibitors show promise for treating inflammatory diseases like arthritis by reducing inflammation without causing ulcers. However, potential toxicities and therapeutic superiority over existing NSAIDs require further investigation.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • The discovery of cyclooxygenase-2 (COX-2) has spurred significant research and drug development.
  • Understanding the two COX isoforms (COX-1 and COX-2) offers new insights into disease pathogenesis and physiological regulation.

Purpose of the Study:

  • To evaluate the therapeutic potential and safety of COX-2 selective inhibitors.
  • To assess the validity of the COX-1 and COX-2 hypothesis regarding selective inhibition.

Main Methods:

  • Preliminary in vivo studies with COX-2 selective inhibitors.
  • Analysis of the mechanism of action for traditional NSAIDs and selective COX-2 inhibitors.

Main Results:

  • Selective COX-2 inhibition appears sufficient to reduce inflammation and avoid gastric ulcers.

Related Experiment Videos

  • Potential for shared toxicities (e.g., renal, neurological) with traditional NSAIDs exists.

    • Conclusions:

    • COX-2 selective inhibitors may offer a "better aspirin" for inflammatory arthritides, but caution is needed.
    • While promising for chronic diseases like rheumatoid arthritis (RA) and osteoarthritis (OA) due to reduced NSAID toxicity, further evaluation of efficacy and safety is crucial.